Fig. 1From: Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019Defined daily doses (N, %) and revenues (million €, %) of antiretroviral drugs by patent status between 1/2017 and 2/2019Back to article page